-+ 0.00%
-+ 0.00%
-+ 0.00%

Advanz Pharma's Allergic Asthma Biosimilar Adcomfo Recommended for EU Approval

MT Newswires·09/18/2026 08:00:10
Listen to the news
08:00 AM EDT, 09/18/2026 (MT Newswires) -- Advanz Pharma's Adcomfo drug for severe persistent allergic asthma was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use. Adcomfo, a biosimilar to Roche (RO.SW) unit Genentech and Novartis' (NOVN.SW) Xolair or omalizumab, is indicated as an add-on therapy to improve asthma control in patients aged six and above with severe persistent allergic asthma and who have a positive skin test or in vitro reactivity to a perennial aeroallergen. The drug is also intended as an add-on therapy with intranasal corticosteroids for the treatment of severe chronic rhinosinusitis with nasal polyps in patients aged 18 and above, and for the treatment of chronic spontaneous urticaria in patients aged 12 and above. Adcomfo is pending final marketing approval from the European Commission.